Literature DB >> 16857725

Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha.

Masahiro Itoh1, Miki Nakajima, Eriko Higashi, Ryoko Yoshida, Kiyoshi Nagata, Yasushi Yamazoe, Tsuyoshi Yokoi.   

Abstract

CYP2A6 plays important roles in the metabolism of nicotine and some clinically used drugs. Interindividual variability in the CYP2A6 expression level in human liver might be caused by an inducible property, but the molecular mechanism of induction is unclear. Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes. We identified three direct repeat separated by four nucleotides (DR4)-like elements at -6698, -5476, and -4618 in the CYP2A6 gene, to which PXR and CAR could bind after dimerization with retinoid X receptor (RXR)-alpha. In luciferase assays, overexpression of PXR or CAR could not activate the transcriptional activity of CYP2A6 promoter constructs (-6754 to -1) in HepG2 cells. Cotransfection of hepatocyte nuclear factor-4alpha did not affect the transcriptional activities in the absence or presence of PXR or CAR. Interestingly, cotransfection of peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) as well as PXR significantly enhanced the transcriptional activity (3.9-fold of control). By the deletion of a possible suppresser region (-4533 to -185), the effects of PXR/PGC-1alpha on the transcriptional activity were increased (6.9-fold of control). Deletion or mutation analyses revealed that two DR4-like elements at -5476 and -4618 are essential for transactivation by PXR/PGC-1alpha. Chromatin immunoprecipitation assay revealed that PXR and PGC-1alpha bind to CYP2A6 chromatin. In conclusion, we found that CYP2A6 is induced via PXR and PGC-1alpha through the DR4-like element at the distal response region. This is the first study to report the molecular mechanism of the induction of CYP2A6.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857725     DOI: 10.1124/jpet.106.107573

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

Review 2.  Corepressors of agonist-bound nuclear receptors.

Authors:  Igor Gurevich; Anthony M Flores; Brian J Aneskievich
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-14       Impact factor: 4.219

3.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

4.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Authors:  Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2018-01       Impact factor: 2.089

6.  Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Authors:  Janne Hukkanen; Peyton Jacob Iii; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 7.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

8.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

9.  Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Authors:  Julie-Anne Tanner; Jeffrey A Henderson; Dedra Buchwald; Barbara V Howard; Patricia Nez Henderson; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

10.  Artemisinin and CYP2A6 activity in healthy subjects.

Authors:  Sara Asimus; Trinh Ngoc Hai; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2007-12-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.